Switch theme
Sign up to access all valuation multiples
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chengdu Kanghua has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Chengdu Kanghua achieved revenue of $217M and an EBITDA of $86.8M.
Chengdu Kanghua expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chengdu Kanghua valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $217M | n/a | XXX | XXX | XXX |
| Gross Profit | $167M | $186M | XXX | XXX | XXX |
| Gross Margin | 77% | NaN% | XXX | XXX | XXX |
| EBITDA | $86.8M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 40% | NaN% | XXX | XXX | XXX |
| Net Profit | $114M | $82.4M | XXX | XXX | XXX |
| Net Margin | 53% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Chengdu Kanghua's stock price is CNY 60 (or $8).
Chengdu Kanghua has current market cap of CNY 8.0B (or $1.1B), and EV of CNY 7.5B (or $1.0B).
See Chengdu Kanghua trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.1B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Chengdu Kanghua has market cap of $1.1B and EV of $1.0B.
Chengdu Kanghua's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Chengdu Kanghua's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Chengdu Kanghua and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.0B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpChengdu Kanghua's NTM/LTM revenue growth is n/a
Chengdu Kanghua's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Chengdu Kanghua's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Chengdu Kanghua's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Chengdu Kanghua and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 55% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chengdu Kanghua acquired XXX companies to date.
Last acquisition by Chengdu Kanghua was XXXXXXXX, XXXXX XXXXX XXXXXX . Chengdu Kanghua acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Chengdu Kanghua founded? | Chengdu Kanghua was founded in 2004. |
| Where is Chengdu Kanghua headquartered? | Chengdu Kanghua is headquartered in China. |
| Is Chengdu Kanghua publicy listed? | Yes, Chengdu Kanghua is a public company listed on SHE. |
| What is the stock symbol of Chengdu Kanghua? | Chengdu Kanghua trades under 300841 ticker. |
| When did Chengdu Kanghua go public? | Chengdu Kanghua went public in 2020. |
| Who are competitors of Chengdu Kanghua? | Similar companies to Chengdu Kanghua include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Chengdu Kanghua? | Chengdu Kanghua's current market cap is $1.1B |
| Is Chengdu Kanghua profitable? | Yes, Chengdu Kanghua is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
